HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1)

Bortezomib (Btz) shows robust efficacy in patients with multiple myeloma (MM); however, some patients experience suboptimal responses and show specific toxicities. Therefore, we attempted to identify specific HLA alleles associated with Btz‐related toxicities and response to treatment. Eighty‐two tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ri, Masaki, Iida, Shinsuke, Maruyama, Dai, Sakabe, Aya, Kamei, Ryo, Nakashima, Takuto, Tohkin, Masahiro, Osaga, Satoshi, Tobinai, Kensei, Fukuhara, Noriko, Miyazaki, Kana, Tsukamoto, Norifumi, Tsujimura, Hideki, Yoshimitsu, Makoto, Miyamoto, Kenichi, Tsukasaki, Kunihiro, Nagai, Hirokazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645746/
https://www.ncbi.nlm.nih.gov/pubmed/34626515
http://dx.doi.org/10.1111/cas.15158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645746/
https://www.ncbi.nlm.nih.gov/pubmed/34626515
http://dx.doi.org/10.1111/cas.15158

Ejemplares similares